PEOPLE - Changes at Gambro Holding:
This article was originally published in Clinica
In light of healthcare group Gambro Holding's (Lund, Sweden) restructure into three independent companies (Gambro - renal products; Gambro Healthcare - renal care services; and Gambro BCT - cell therapy and blood products) under the holding entity of Indap AB, four executive leadership appointments have been announced. Peter Sjostrand is elected chairman of Gambro, succeeding Massimo Rossi, who has become chairman of Indap. And Thomas Glanzmann has been named CEO, succeeding Jan Bruneheim, who has become CEO of Indap.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.